Literature DB >> 28634704

Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?

E Piantanida1, L Bartalena2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28634704     DOI： 10.1007/s40618-017-0717-8

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  10 in total

Review 1.  Graves' Disease.

Authors:  Terry J Smith; Laszlo Hegedüs
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

2.  Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

Authors:  Marius N Stan; James A Garrity; Barbara G Carranza Leon; Thapa Prabin; Elizabeth A Bradley; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2014-10-24       Impact factor: 5.958

Review 3.  MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.

Authors:  Marius N Stan; Mario Salvi
Journal:  Eur J Endocrinol       Date:  2016-10-19       Impact factor: 6.664

4.  Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

5.  Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?

Authors:  L Bartalena; G Veronesi; G E Krassas; W M Wiersinga; C Marcocci; M Marinò; M Salvi; C Daumerie; C Bournaud; M Stahl; L Sassi; C Azzolini; K G Boboridis; M P Mourits; M R Soeters; L Baldeschi; M Nardi; N Currò; A Boschi; M Bernard; G von Arx; P Perros; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2017-02-07       Impact factor: 4.256

6.  Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.

Authors:  L Bartalena; G E Krassas; W Wiersinga; C Marcocci; M Salvi; C Daumerie; C Bournaud; M Stahl; L Sassi; G Veronesi; C Azzolini; K G Boboridis; M P Mourits; M R Soeters; L Baldeschi; M Nardi; N Currò; A Boschi; M Bernard; G von Arx
Journal:  J Clin Endocrinol Metab       Date:  2012-10-04       Impact factor: 5.958

7.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

Review 8.  Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.

Authors:  Wilmar M Wiersinga
Journal:  Lancet Diabetes Endocrinol       Date:  2016-06-23       Impact factor: 32.069

9.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

Review 10.  Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).

Authors:  L Bartalena; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2016-06-18       Impact factor: 4.256
  10 in total
  7 in total

1.  Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?

Authors:  M L Tanda; E Piantanida; E Masiello; C Cusini; L Bartalena
Journal:  J Endocrinol Invest       Date:  2019-02-04       Impact factor: 4.256

2.  Oxidative Stress in Graves Disease and Graves Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2020-11-20

3.  Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Authors:  M Leo; E Sabini; I Ionni; A Sframeli; B Mazzi; F Menconi; E Molinaro; F Bianchi; F Brozzi; P Santini; R Elisei; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-08-30       Impact factor: 4.256

Review 4.  Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

Authors:  M Marinò; I Ionni; G Lanzolla; A Sframeli; F Latrofa; R Rocchi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-11-05       Impact factor: 5.467

5.  Teprotumumab: a disease modifying treatment for graves' orbitopathy.

Authors:  Michelle Ting; Daniel G Ezra
Journal:  Thyroid Res       Date:  2020-07-04

Review 6.  Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.

Authors:  Giulia Lanzolla; Guia Vannucchi; Ilaria Ionni; Irene Campi; Federica Sileo; Elisa Lazzaroni; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-22       Impact factor: 5.555

Review 7.  Orbital Signaling in Graves' Orbitopathy.

Authors:  Mohd Shazli Draman; Lei Zhang; Colin Dayan; Marian Ludgate
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-09       Impact factor: 5.555
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.